ANAPLASTIC LARGE CELL LYMPHOMA TREATMENT ROAD MAP (Modified ALCL99)
|
|
- Hilary Benson
- 5 years ago
- Views:
Transcription
1 ANAPLASTIC LARGE CELL LYMPHOMA TREATMENT ROAD MAP (Modified ALCL99) CLASSIFICATION OF TREATMENT GROUPS: 1. Isolated Skin lesions, < 5 skin lesions. Treatment course: ( No treatment, wait and see approach) 2. Low Risk ( completely resected isolated skin lesion): TREATMENT COURSE : ProPhase Cycle A1 cycle B1, Cycle A2 (3 cycles) 3. Standard Risk (No skin involvement proven by biopsy, No mediastinal involvement, no liver, lung, or spleen involvement) TREATMENT COURSE: Prophase Cycle A1 Cycle B1, Cycle A2 Cycle B2 Cycle A3, Cycle B3 (6 cycles) 4. High Risk( Presence of biopsy proven skin lesions, mediastinal involvement, liver enlargement 5 cm, or nodular liver, spleen enlargement or nodular spleen, lung involvement. TREATMENT COURSE: Prophase Cycle A1 Cycle B1, Cycle A2 Cycle B2 Cycle A3, Cycle B3 (6 cycles) REQUIREMENTS FOR STARTING CHEMOTHERAPY TREATMENT COURSE Cycle 1: should begin on Day 6 of the prophase. Subsequent Cycles: should begin on Day 22 of the previous cycle when peripheral counts have recovered with ANC 500/mm3 and platelets 50,000/mm3 (whichever occurs later). Therapy may be delayed for sever complication. TREATMENT SCHEDULE Cycle Day Given date Cycle Length Chemotherapy treatment Pro-Phase 0 5 Days Cyclophosphamide Day 1&2 Dexamethasone Day 1-5 Triple Intrathecal Day 1 Cycle A Days Dexamethasone Day1-5 Ifosfamide Days 1-5 Cytarabine days 4&5 Etoposide Days 4 &5 Cycle B Days Dexamethasone Day 1-5 Cyclophosphamide Days 1-5 Doxorubicine Days 4 & 5 Cycle A Days Dexamethasone Day1-5 Ifosfamide Days 1-5 Cytarabine days 4&5 Etoposide Days 4 &5 Cycle B Days Dexamethasone Day 1-5 Cyclophosphamide Days 1-5 Doxorubicine Days 4 & 5 Cycle A Days Dexamethasone Day1-5 Ifosfamide Days 1-5 Cytarabine days 4&5 Etoposide Days 4 &5 Cycle B Days Dexamethasone Day 1-5 Cyclophosphamide Days 1-5 Doxorubicine Days 4 & 5 Work up CBC/diff/plts, Renal Profile, Electrolytes, LFT s,urinalysis BM aspirate, Scans ( CT or MRI, Bone Scan for bone primary disease only, ECHO/EKG CBC/diff/plts, Renal Profile, Electrolytes, LFT s,urinalysis CBC/diff/plts, Renal Profile, Electrolytes, LFT s,urinalysis BM aspirate, Scans ( CT or MRI, Bone Scan for bone primary disease only All sites of disease should be evaluated after CycleB1 and after Cycle B2 if not in CR or CRU after Cycle B1. (After cycle B1, if positive at diagnosis) CBC/diff/plts, Renal Profile, Electrolytes, LFT s,urinalysis CBC/diff/plts, Renal Profile, Electrolytes, LFT s,urinalysis, Echo/EKG BM aspirate, Scans ( CT or MRI, Bone Scan for bone primary disease only All sites of disease should be evaluated after CycleB1 and after Cycle B2 if not in CR or CRU after Cycle B1. (After cycle B1, if positive at diagnosis) CBC/diff/plts, Renal Profile, Electrolytes, LFT s,urinalysis CBC/diff/plts, Renal Profile, Electrolytes, LFT s,urinalysis BM aspirate, Scans ( CT or MRI, Bone Scan for bone primary disease only, ECHO/EKG KING FAISAL SPECIALIST HOSPITAL (General Organization)
2 ANAPLASTIC LARGE CELL LYMPHOMA TREATMENT ROAD MAP (Modified ALCL99) DOSES AND ADMINISTRATION SCHEDULE Drug Route Dosage Patient weight < 10 Kg Pro- Phase Cyclophosphamide (CPM) IV over minutes PO /IV 0.17mg/kg/dose once a day on days 1 Dexamethasone and 2 (DEX) 0.17 mg/kg/dose BID on days 3-5 Intrathecal Triple Therapy (ITT) Cycle A1, A2, and A3 IT Patient weight 10 Kg 7 mg/kg/dose Daily 200 mg/m2/dose Daily Days 1& 2 Age(yrs) Dose MTX: 8mg, HC: 8mg, ARAC: 15mg MTX: 10mg, HC: 10mg, ARAC: 20mg MTX: 12mg, HC: 12mg, ARAC: 25mg 3 MTX: 15mg, HC: 15mg, ARAC: 30mg 5 mg/m2/dose once a day on days 1 and 2 5 mg/m2/dose BID on days 3-5 Administration Schedule Once daily on Days 1 & 2 BID Days 3-5 Dexamethasone (DEX) PO /IV 0.17 mg/kg/dose BID on days mg/m2/dose BID on days 1-5 BID on Days 1-5 Ifosfamide (IFOS) IV over 2 27 mg/kg /dose once daily Days mg/m 2 /dose once daily Days 1-5 On day 1 administer prior to MTX hours Mesna IV 6 mg/kg /dose ( total 16mg/kg/day) 160 mg/m 2 /dose ( total 480 mg/m2/day) On days 1-5, at hours 0,4,and 8 following ifosfamide on days 1-5 Methotrexate (MTX) IV over 3 hours 100mg/kg/dose once on day one 3000 mg/m 2 /dose once on day one Leucovorine IV /PO 15 mg/m2/dose every 6 hours, Start 24 hours from the start of MTX infusion, continue till MTX level < 0.1µM/L Cytrabine( ARAC) IV Over 1 hour Etoposide (ETOP) IV over 2 hours * Cycle B1, B2, and B3 5 mg/kg/dose every 12 hours on days 4 and mg/kg/dose once daily on days 4 and mg/m 2 /dose every 12 hours on days 4 and mg/m 2 /dose once daily on days 4 and 5 Day 1 Give over 1 hour every 12 hours for total of 4 doses Begin after completion of Cytarabine dose each day Dexamethasone (DEX) PO /IV 0.17 mg/kg/dose BID on days mg/m 2 /dose BID on days 1-5 BID on Days 1-5 Cyclophosphamide (CPM) IV over 1 7 mg/kg/dose Daily days mg/m 2 /dose Daily days 1-5 Give prior to MTX on day 1 hour Methotrexate (MTX) IV over 3 hours 100mg/kg/dose once on day one 3000 mg/m 2 /dose once on day one Leucovorine IV /PO 15 mg/m2/dose every 6 hours, Start 24 hours post the start of MTX infusion, continue till MTX level < 0.1µM/L DOXOrubicin(DOXO) IV over 30 min 0.8 mg/m2/dose days 4&5 25mg/m 2 /dose days 4&5 Given IV over 30 minutes *Or as per Pharmacy approved administration guidelines KING FAISAL SPECIALIST HOSPITAL (General Organization)
3 DATE / TIME CHEMOTHERAPY (Cyclophosphamide/Dexamethasone/Triple intrathecal) Anaplastic large Cell Lymphoma (Pro-Phase) Diagnosis: ANL Week: Allergies: CHE CK Height: cm Weight: kg BSA: m 2 Dose reduction: No Yes % dose reduction IV Access: Peripheral Central Labs: CBCD, RHP, UA, MRD Lab Value Parameters: Initiate chemotherapy if ANC 500,Platelets 50,000, Normal ALT, Normal Bilirubin Normal creatinine, urine specific gravity Pre and Post Hydration: for all patients D5- ½ NS+ mmol per liter KCL, at (125ml/m2/hr) = ml/hr for day 1 and 2 Or Pre-chemotherapy: Check appropriate dose Ondansetron (0.15mg/kg/dose ) 1mg, 2mg, 4mg, 8mg IVPB 30 minutes prior to chemotherapy and then PO every 8 hours for 2 days Granisetron (20-40 Mcg/Kg/dose) 0.1mg 0.2mg 0.4mg 0.6mg 0.8mg 1mg 15 min prior to chemotherapy daily for 2 days. Chemotherapy: Begin chemotherapy on: (Specify date): / / (dd/mm/yyyy) Children with body weight 10kg: Dexamethasone (0.17mg/kg/dose) = mg IV/ PO over 10 minutes on day 1&2 Dexamethasone (0.17mg/kg/dose) = mg IV/ PO BID over 10 minutes on day 3-5 Cyclophosphamide (7 mg/kg)= mg IVPB over 30 minuts on days 1 &2 Children with body weight >10 kg: Dexamethasone (5 mg/m 2 /dose) = mg IV/ PO over 10 minutes on day 1&2 Dexamethasone (5 mg/m 2 /dose) = mg IV/ PO BID over 10 minutes on day 3-5 Cyclophosphamide (200mg/m 2 /dose)= mg IVPB over 30 minuts on days 1 &2 Triple Intrathecal Therapy Begin therapy on (Specify date): / / / (dd/mm/yyyy) yrs Methotrexate 8mg, Hydrocortisone 8mg, Cytarabine 15mg yrs Methotrexate 10mg, Hydrocortisone 10mg, Cytarabine 20mg Yrs Methotrexate 12mg, Hydrocortisone 12mg, Cytarabine 25mg >3 Yrs Methotrexate 15mg, Hydrocortisone 15mg, Cytarabine 30mg Physician Signature: Physician Co-Signature: (Page 1 of 1) Pager: Pager: Date: Date:
4 DATE / TIME Or Chemotherapy(Ifosfamide/Methotrexate/Cytarabine/Etoposide) ANAPLASTIC LARGE CELL LYMPHOMA (Cycle A) Diagnosis: Standard Risk ANPL High Risk ANPL Cycle Day: Allergies: Height: cm Weight: kg BSA: m 2 Dose reduction: No Yes % dose reduction Nursing Orders: Strict intake/output Daily weight Urine specific gravity every 4 hrs, notify MD for specific gravity > 1.01 Dipstick urine every shift to maintain urine ph between 7-8(Until MTX level <0.1 micromolar) IV Access: Peripheral Central Chemotherapy Parameters: Initiate chemotherapy if ANC 500,Platelets 50,000, Alt 300units/L, normal Bilirubin Normal Creatinine, urine ph 7.0, urine specific gravity MTX level 24, 48 & 72 hours after the start of Methotrexate until MTX level <0.1 micromolar Pre-chemotherapy: Check appropriate dose Ondansetron (0.15mg/kg) 1mg, 2mg, 4mg, 8mg IVPB 30 minutes prior to chemotherapy and then every 8 hours daily for 5 days. Granisetron (20-40mcg/kg/dose) 0.1mg 0.2mg 0.3mg 0.4mg 0.6mg 0.8mg 1mg IVPB over 15 minutes prior to chemotherapy and every 12 hours if needed daily for 5 days. PRE- IFOSFAMIDE HYDRATION: D 5 W-½ NS + Potassium Chloride mmol per liter + Magnesium sulfate - mmol per liter to run at (125ml/m 2 /hr)= ml/hr to achieve urine specific gravity prior start of ifosfamide PRE AND POST METHOTREXATE HYDRATION ( to start post Ifosfamide infusion) D5-1/2 NS + Sodium Bicarbonate 40 mmol per liter + Potassium Chloride mmol per liter at (125ml/m 2 /hr)= ml/hr until MTX level < 0.1 micromolar (1x10-7 molar) Post- IFOSFAMIDE HYDRATION (tostart following clearance of methotrexate) D 5 W-½ NS + Potassium Chloride mmol per liter + Magnesium sulfate - mmol per liter to run at (125ml/m 2 /hr)= ml/hr to continue for 12 hours post last Ifosfamide dose (Page 1 of 3)
5 DATE / TIME Chemotherapy(Ifosfamide/Methotrexate/Cytarabine/Etoposide) ANAPLASTIC LARGE CELL LYMPHOMA (Cycle A) Chemotherapy: Begin chemotherapy on (Specify date): ( / / ) (dd/mm/yyyy) Children with body weight 10kg: Ifosfamide (27 mg / kg/dose)= mg IVPB Once daily for 5days( Day1-5). Mesna (6 mg / kg/dose) = mg IVPB over 15 minutes immediately prior to Ifosfamide and then at 4 and 8 hours after start of Ifosfamide daily for 5 days. Methotrexate (100mg/kg/dose )= mg in 500 ml Dextrose to run over 3 hours once on day one to start after compleation of ifosfamide infusion Leucovorin (15mg/m 2 /dose)= mg IV/PO every 6 hrs until MTX level 0.1 micromolar (1x10-7 molar). Begin 24 hrs after the completion of the Methotrexate infusion Cytarabine (5mg/kg/dose)= mg IVPB every 12 hoursfor 2 doses ( days 4 and 5) Etoposide (3.5 mg/kg/dose)= mg IVPB once daily for 2 doses( Days 4 and 5) Children with body weight >10kg: Ifosfamide (800 mg / m 2 /dose)= mg IVPB Once daily for 5days( Day1-5). Mesna (160mg / m 2 /dose) = mg IVPB over 15 minutes immediately prior to Ifosfamide and then at 4 and 8 hours after start of Ifosfamide daily for 5 days. Methotrexate (3000mg/ m 2 /dose )= mg in 500 ml Dextrose to run over 3 hours once on day one to start after compleation of ifosfamide infusion Leucovorin (15mg/m 2 /dose)= mg IV/PO every 6 hrs until MTX level 0.1 micromolar (1x10-7 molar). Begin 24 hrs after the start of the Methotrexate infusion Cytarabine (150mg/ m 2 /dose)= mg IVPB every 12 hours for 2 doses ( days 4 and 5) Etoposide (100mg/ m 2 /dose)= mg IVPB once daily for 2 doses( Days 4 and 5) Physician Signature ID: Pager Date: KING FAISAL SPECIALIST HOSPITAL (Page 2 of 3)
6 DATE / TIME Chemotherapy(Ifosfamide/Methotrexate/Cytarabine/Etoposide) ANAPLASTIC LARGE CELL LYMPHOMA (Cycle A) In-case of reaction to Etoposide: Epinephrine ( in case of anaphylactic reaction) 1:1000 (0.01ml/kg) ml SC (max-0.5ml) Hydrocortisone (5 mg/kg)= mg IVP Diphenhydramine (0.5 mg/kg- max 50mg)= mg IVP Additional medications/orders: (for delayed nausea and vomiting post Cisplatin) Metoclopramide (0.5mg/kg-max 10mg)= mg IVPB every 6 hours PRN. Diphenhydramine (0.5mg/kg-max 25mg)= mg IV every 6 hours PRN. Begin with first dose of Metoclopramide and d/c after last dose of Metoclopramide given. Chemotherapy Precautions Avoid administration of Septra, Penicillins, Tazocin, any nonsteroidal antiinflamatory medications,penicillins, proton pump inhibitors, and Imatinib during MTX infusion and for At least 72 hours after the start of the infusion, and until MTX level < 0.1 Micromolar/L (Page 3 of 3)
7 DATE / TIME Or Chemotherapy (Dexamethasone/Methotrexate/Cyclophosphamide/Doxorubicin) ANAPLASTIC LARGE CELL LYMPHOMA (Cycle B) Diagnosis: Standard Risk ANPL High Risk ANPL Cycle Day: Allergies: Height: cm Weight: kg BSA: m 2 Dose reduction: No Yes % dose reduction IV Access: Peripheral Central Nursing Orders: Strict intake/output Daily weight Urine specific gravity every 4 hrs, notify MD for specific gravity > Dipstick urine every shift to maintain urine ph between 7-8(Until MTX level <0.1 micromolar) Labs: CBCD, RHP, UA, MRD before starting, ECHO Laboratory Parameters: Initiate chemotherapy if ANC 500,Platelets 50,000, Alt 300units/L, normal Bilirubin Normal Creatinine, urine ph 7.0, urine specific gravity MTX level 24, 48 & 72 hours after the start of Methotrexate until MTX level <0.1 micromolar Pre-chemotherapy: Check appropriate dose Ondansetron (0.15mg/kg) 1mg, 2mg, 4mg, 8mg IVPB 30 minutes prior to chemotherapy and then every 8 hours daily for 5 days. Granisetron (20-40mcg/kg/dose) 0.1mg 0.2mg 0.4mg 0.6mg 0.8mg 1mg IVPB over 15 minutes prior to chemotherapy and every 12 hours if needed daily for 5 days. PRE-HYDRATION D5-1/2 NS + Sodium Bicarbonate 40 mmol per liter + Potassium Chloride mmol per liter at (125ml/m 2 /hr)= ml/hr until MTX level < 0.1 micromolar (1x10-7 molar) Post- MTX HYDRATION (tostart following clearance of methotrexate) D 5 W-½ NS + Potassium Chloride mmol per liter + Magnesium sulfate - mmol per liter to run at (125ml/m 2 /hr)= ml/hr to continue for 5 days till last dose Of cyclophosphamide Chemotherapy Precautions Avoid administration of Septra, Penicillins, Tazocin, any nonsteroidal antiinflamatory medications,penicillins, proton pump inhibitors, and Imatinib during MTX infusion and for At least 72 hours after the start of the infusion, and until MTX level < 0.1 Micromolar/L (Page 1 of 2)
8 DATE / TIME Chemotherapy (Dexamethasone/Methotrexate/Cyclophosphamide/Doxorubicin) ANAPLASTIC LARGE CELL LYMPHOMA (Cycle B) Chemotherapy: Begin chemotherapy on (Specify date): ( / / ) (dd/mm/yyyy) Children with body weight 10kg: Dexamethasone (0.17mg/kg/dose) = mg IV/ PO BID over 10 minutes on day 1-5 Cyclophosphamide (7 mg/kg)= mg IVPB over 30 minutes on days 1-5 Methotrexate (100mg/kg/dose )= mg in 500 ml Dextrose to run over 3 hours once on day one to start after compleation of cyclophosphsamind infusion Leucovorin (15mg/m 2 /dose)= mg IV/PO every 6 hrs until MTX level 0.1 micromolar (1x10-7 molar). Begin 24 hrs after the completion of the Methotrexate infusion DoxoRubicin (0.8 mg/kg/dose)= mg IVPB over 30 minutes on days 4 and 5 Children with body weight >10kg: Dexamethasone (5 mg/m 2 /dose) = mg IV/ PO BID over 10 minutes on days 1-5 Cyclophosphamide (200mg/m 2 /dose)= mg IVPB over 30 minutes on days 1-5 Methotrexate (3000mg/ m 2 /dose )= mg in 500 ml Dextrose to run over 3 hours once on day one to start after compleation of cyclophosphsamind infusion Leucovorin (15mg/m 2 /dose)= mg IV/PO every 6 hrs until MTX level 0.1 micromolar (1x10-7 molar). Begin 24 hrs after the completion of the Methotrexate infusion DoxoRubicin (25mg/m2/dose)= mg IVPB over 30 minutes on days 4 and 5 In-case of reaction to Etoposide: Epinephrine ( in case of anaphylactic reaction) 1:1000 (0.01ml/kg) ml SC (max-0.5ml) Hydrocortisone (5 mg/kg)= mg IVP Diphenhydramine (0.5 mg/kg- max 50mg)= mg IVP Additional medications/orders: (for delayed nausea and vomiting post Cisplatin) Metoclopramide (0.5mg/kg-max 10mg)= mg IVPB every 6 hours PRN. Diphenhydramine (0.5mg/kg-max 25mg)= mg IV every 6 hours PRN. Begin with first dose of Metoclopramide and d/c after last dose of Metoclopramide given. Physician Signature ID: Pager Date: (Page 2 of 2)
LYIVAC (Magrath B) + R (rituximab) [To be used after LYCODOX-M (Magrath A) + R]
Page 1 of 7 PPO FOR THE TREATMENT OF BURKITT LYMPHOMA AND LEUKEMIA LYIVAC (Magrath B) + R (rituximab) [To be used after LYCODOX-M (Magrath A) + R] DAY DATE CHEMOTHERAPY 1 Start signature sheet and prednisolone
More informationHigh Dose Cytarabine plus high dose Methotrexate for CNS Lymphoma
High Dose Cytarabine plus high dose Methotrexate for CNS Lymphoma Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton
More informationZzbeacon,Zayna [MR ]
AALL1131 INTERIM MAINTENANCE, HR-ALL, ARM B, HD MTX Properties Cycle 1 9/27/2012 through 11/28/2012 (63 days), Planned Day 1, Cycle 1 Planned for 9/27/2012 Release CBC and differential Release Release
More informationBurkitt s Lymphoma or DLBCL with adverse features PATIENTS WITH GOOD PERFORMANCE STATUS
Regimen R-CODOX M Indication Burkitt s Lymphoma or DLBCL with adverse features Therapeutic Intent Radical/Curative PATIENTS WITH GOOD PERFORMANCE STATUS Day Medication Dose Route Administration Details
More informationVincristine Ifosfamide Doxorubicin Etoposide (VIDE) Sarcoma
Systemic Anti Cancer Treatment Protocol Vincristine Ifosfamide Doxorubicin Etoposide (VIDE) Sarcoma PROTOCOL REF: MPHAVIDE (Version No: 1.0) Approved for use in: Ewings sarcoma Desmoplastic small round
More informationDERBY-BURTON LOCAL CANCER NETWORK FILENAME SMILE.DOC CONTROLLED DOC NO: HCCPG B57 CSIS Regimen Name: SMILE. SMILE chemotherapy
SMILE chemotherapy Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient Indication Extranodal
More informationDoxorubicin and Ifosfamide Sarcoma
Systemic Anti Cancer Treatment Protocol Doxorubicin and Ifosfamide Sarcoma PROTOCOL REF: MPHADOXIFO (Version No:.0) Approved for use in: Soft tissue sarcoma Dosage: Drug Dosage Route Frequency Doxorubicin
More informationCisplatin Doxorubicin Sarcoma
Systemic Anti Cancer Treatment Protocol Cisplatin Doxorubicin Sarcoma PROCEDURE REF: MPHACISDOX (Version No. _1.0) Approved for use in: Osteosarcoma Palliative / advanced disease Not suitable for PAM schedule
More informationADULT Updated: September 4, 2018
Updated: September 4, 2018 Regimen Reference Order ARIA: LYMP [R-CHOP alt. R-DHAP] Planned Course: Indication for Use: Every 21 days for 6 cycles (R-CHOP given on cycles 1, 3 and 5; R-DHAP given on cycles
More information(R) CODOX M / (R) IVAC
(R) CODOX M / (R) IVAC Indication Burkitt's or Burkitt's-like lymphoma, especially those with 1 or more of the following poor risk criteria: - Raised LDH level - WHO performance status 2-4 - Ann Arbor
More informationTIP Paclitaxel, Ifosfamide and Cisplatin
Systemic Anti Cancer Treatment Protocol TIP Paclitaxel, Ifosfamide and Cisplatin PROTOCOL REF: MPHATIPGC (Version No: 1.0) Approved for use in: Second line treatment of germ cell tumours Dosage: Drug Dosage
More informationLung Pathway Group Cisplatin & IV Vinorelbine in Non- Small Cell Lung Cancer (NSCLC)
Lung Pathway Group Cisplatin & IV Vinorelbine in Non- Small Cell Lung Cancer (NSCLC) Indication: First line in radical/induction treatment in locally advanced NSCLC First line palliative treatment in advanced/metastatic
More informationELIGIBILITY: small cell or neuroendocrine cancer (pure or mixed) administration of this protocol is restricted to BCCA Cancer Centres
BCCA Protocol Summary for Treatment of Small Cell or Neuroendocrine Carcinoma of Gynecologic System Origin using PACLitaxel, CISplatin, Etoposide and CARBOplatin with Radiation (GO 95 02) Protocol Code:
More informationGemcitabine + Cisplatin Regimen
Gemcitabine + Cisplatin Regimen Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient Indication
More information1.28 Protocol Name: CODOX-M/IVAC
1.28 Protocol Name: CODOX-M/IVAC Indication Burkitt's or Burkitt's-like lymphoma - especially those with 1 of the following poor risk criteria: Lymphoblastic lymphoma - especially B subtype Acute Myeloid
More informationALL Phase 2 Induction (25-60 years)
ALL Phase 2 (25-60 years) INDICATION of remission in Adult Acute Lymphoblastic Leukaemia (ALL) patients This protocol is suitable for patients aged 25-60 years. It may sometimes be used in older patients
More informationCisplatin and Gemcitabine Bladder Cancer: Full and split dose
Systemic Anti Cancer Treatment Protocol Cisplatin and Gemcitabine Bladder Cancer: Full and split dose PROCTOCOL REF: MPHAUROCIG (Version No: 1.0) Approved for use in: Neoadjuvant and palliative indications
More informationDERBY-BURTON LOCAL CANCER NETWORK FILENAME ESHAP.DOC CONTROLLED DOC NO: HCCPG B44. ESHAP Regimen
ESHAP Regimen Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient Indication Relapsed/ refractory
More informationInternational Pleuropulmonary Blastoma (PPB) Treatment and Biology Registry. Types I, II and III PPB
CHILDREN S HOSPITALS AND CLINICS of MINNESOTA 2525 Chicago Avenue South Minneapolis, Minnesota 55404, USA International Pleuropulmonary Blastoma (PPB) Treatment and Biology Registry Types I, II and III
More informationVIP (Etoposide, Ifosfamide and Cisplatin)
VIP (Etoposide, Ifosfamide and Cisplatin) Indication First line treatment for metastatic seminoma, non seminoma or combined tumours where bleomycin is contra-indicated. Usually used for patients with intermediate
More informationLung Pathway Group Cisplatin & PO Vinorelbine in Non- Small Cell Lung Cancer (NSCLC)
Lung Pathway Group Cisplatin & PO Vinorelbine in Non- Small Cell Lung Cancer (NSCLC) Indication: First line in radical/induction treatment in locally advanced NSCLC First line palliative treatment in advanced/metastatic
More informationRITUXIMAB RHEUMATOLOGY VASCULITIS
. PHYSICIAN (Patient Sticker) ORDER SET : CDH 208-237 Approved - Page 1 of 5 Patient: DOB: Gender: Patient Phone #: Height: Weight: Diagnosis: ICD-10 Code: Treatment Start Date: Provider Facility Name:
More informationZzbeacon,Zayna [MR ]
AALL1131-DS INDUCTION HR-ALL, DAYS 1-14 Properties Cycle 1 9/27/2012 through 10/10/2012 (14 days), Planned Day 1, Cycle 1 Planned for 9/27/2012 Release Labs CBC and differential Release Release Comprehensive
More informationBCCA Protocol Summary for Treatment of Primary Intracerebral Lymphoma with High Dose Methotrexate
BCCA Protocol Summary for Treatment of Primary Intracerebral Lymphoma with High Dose Methotrexate Protocol Code Tumour Group Contact Physician LYHDMTXP Lymphoma Dr. Diego Villa ELIGIBILITY: 1. Age: 16
More information1 Acute Lymphoblastic Leukaemia
1 Acute Lymphoblastic Leukaemia 1.05 Intensification - Philadelphia Negative Patients Indication ALL Philadelphia negative patients Pre-treatment Evaluation The intensification module begins two weeks
More information(primary CNS lymphoma)
(primary CNS lymphoma) INDICATION CNS Lymphoma TREATMENT INTENT Curative PRE-ASSESSMENT 1. Ensure histology is confirmed and documented in the notes. Although it is sometimes difficult to obtain tissue
More informationR-GDP: Rituximab, Gemcitabine, Dexamethasone &Cisplatin
: Rituximab, Gemcitabine, Dexamethasone &Cisplatin INDICATION Relapsed or refractory Hodgkin and non-hodgkin lymphoma. Omit Rituximab for patients with Hodgkin Lymphoma or high grade T cell non-hodgkin
More informationTHE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST. Systemic Anti Cancer Treatment Protocol. EDP + mitotane
Systemic Anti Cancer Treatment Protocol EDP + mitotane PROCEDURE REF: MPHAHANEDP (Version No: 1.0) Approved for use in: Symptomatic treatment for advanced (unresectable, metastatic or relapsed) adrenocortical
More informationPVACE-BOP (Hodgkin s Lymphoma)
DRUG ADMINISTRATION SCHEDULE Day Drug Dose Route Diluent Rate 1 Ondansetron 8mg IV / Oral vinblastine 6mg/m 2 (Max: 10mg) IV Infusion Etoposide 100mg/m 2 IV infusion Patients over 65 years by 15 min infusion
More informationPaclitaxel/Carboplatin with dose dense EC Neoadjuvant Regimen
Systemic Anti Cancer Treatment Protocol Paclitaxel/Carboplatin with dose dense EC Neoadjuvant Regimen PROTOCOL REF: MPHAPCECBR (Version No: 1.0) Approved for use in: Neoadjuvant treatment of operable,
More informationDERBY-BURTON LOCAL CANCER NETWORK FILENAME R-CODOX-M.DOC CONTROLLED DOC NO: HCCPG B115 CSIS Regimen Name: R-CODOXM. Rituximab + CODOX-M
Rituximab + CODOX-M Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient Indication Burkitt
More informationCisplatin Vinorelbine (Oral) therapy +/- radiotherapy
1 REGIMEN TITLE: Cisplatin Vinorelbine (Oral) therapy +/- radiotherapy Page 1 of 5 Indication: First line in Radical/ Induction, Adjuvant and Advanced & Palliative treatment of Non-small cell lung cancer
More informationECX. Anti-emetics: Day 1: highly emetogenic Days 2 21: mildly emetogenic
Page 1 of 5 As an alternative to ECF: For locally advanced (inoperable) or metastatic oesophageal or gastric cancer; peri-operative use in oesophageal or gastric cancer; adenocarcinoma of unknown primary
More informationCisplatin + Etoposide IV / Oral therapy followed by Chemo-radiotherapy in Small Cell Carcinoma of the Cervix
Cisplatin + Etoposide IV / Oral therapy followed by Chemo-radiotherapy in Small Cell Carcinoma of the Cervix Indication: Neoadjuvant chemotherapy followed by Chemo-radiotherapy in Small Cell Carcinoma
More informationR-IDARAM. Dexamethasone is administered as an IV infusion in 100mL sodium chloride 0.9% over 30 minutes.
R-IDARAM Indication Secondary CNS lymphoma ICD-10 codes Codes with a prefix C85 Regimen details Day Drug Dose Route 1 Rituximab 375mg/m 2 IV infusion 1 Methotrexate 12.5mg Intrathecal 1 Cytarabine 70mg
More informationGemcitabine, Dexamethasone and Cisplatin GDP Regimen
Gemcitabine, Dexamethasone and Cisplatin GDP Regimen Available for Routine Use in Burton in-patient N/A Derby in-patient Burton day-case Derby day-case Burton outreach chemotherapy clinic N/A Derby outreach
More informationR-ICE Regimen- Rituximab, Etoposide, Ifosfamide (with MESNA), Carboplatin (+ Depocyte if CNS involvement)
R-ICE Regimen- Rituximab, Etoposide, Ifosfamide (with MESNA), Carboplatin (+ Depocyte if CNS involvement) Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case
More informationStRs and CT doctors in haematology. September Folinic acid dose modified.
High dose Methotrexate and folinic acid rescue Full Title of Guideline: Author (include email and role): Division & Speciality: Clinical Guideline Review Date September 2018 GUIDELINE FOR THE USE OF HIGH
More informationSMILE (Etoposide, Ifosfamide, Methotrexate and Dexamethasone)
SMILE (Etoposide, Ifosfamide, Methotrexate and Dexamethasone) INDICATION Natural Killer/T-cell lymphoma TREATMENT INTENT Curative SPECIAL PRECAUTIONS This protocol causes marked myelosuppression despite
More informationPICU CARD SURG Post Operative Cardiac Transplant Age LESS than 6 months (Page 1 of 5)
(Page 1 of 5) Code Status Full code Status/Admit/Transfer/Discharge Surgical Procedure(s) and date performed (if applicable): Cardiologist: Cardiac Surgeon: Intensivist: Patient Care CMV status Donor CMV
More informationR-GDP: Rituximab, Gemcitabine, Dexamethasone &Cisplatin
: Rituximab, &Cisplatin INDICATION Relapsed or refractory Hodgkin and non-hodgkin lymphoma. Omit Rituximab for patients with Hodgkin Lymphoma. TREATMENT INTENT Palliative or curative depending on context.
More informationALCL 99. International protocol for the treatment of childhood anaplastic large cell lymphoma
ALCL 99 International protocol for the treatment of childhood anaplastic large cell lymphoma November 1999 1. BACKGROUND...4 1.1. RESULTS OF THE DIFFERENT EUROPEAN NATIONAL PROTOCOLS...4 1.1.1. BFM studies...4
More informationELIGIBILITY: Newly diagnosed acute promyelocytic leukemia (APL) with high risk (WBC more than 10 x 10 9 /L)
BC Cancer Protocol Summary for First-Line Induction and Consolidation Therapy of Acute Promyelocytic Leukemia Using Arsenic Trioxide, Tretinoin (All-Trans Retinoic Acid) and DAUNOrubicin Protocol Code
More informationDERBY-BURTON LOCAL CANCER NETWORK FILENAME R-IVE.DOC CONTROLLED DOC NO: HCCPG B53 CSIS Regimen Name: R-IVE. R-IVE Regimen
R-IVE Regimen Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient Indication Relapsed/ refractory
More informationRituximab, Gemcitabine, Dexamethasone and Cisplatin RGDP Regimen
Rituximab, Gemcitabine, Dexamethasone and Cisplatin RGDP Regimen Available for Routine Use in Burton in-patient N/A Derby in-patient Burton day-case Derby day-case Burton outreach chemotherapy clinic N/A
More informationULYRICE. Protocol Code. Lymphoma. Tumour Group. Dr. Laurie Sehn. Contact Physician
BCCA Protocol Summary for the Treatment of Relapsed or Refractory Advanced Stage Aggressive B-Cell Non-Hodgkin s Lymphoma with Ifosfamide, CARBOplatin, Etoposide and rituximab Protocol Code Tumour Group
More informationCisplatin and Vinorelbine and radiotherapy (NSCLC)
Cisplatin and Vinorelbine and radiotherapy (NSCLC) Indication First-line chemotherapy for use with concomitant radical radiotherapy for early or locally advanced non-small cell carcinoma (NSCLC) ICD-10
More informationPREHYDRATION: 1000 ml NS with potassium chloride 20 meq and magnesium sulphate 2 g IV over 1 hour prior to CISplatin
BC Cancer Protocol Summary for Treatment of Newly Diagnosed Nasal, Extranodal Natural Killer (NK) or T-cell lymphoma, using Concurrent Radiation and weekly CISplatin followed by Etoposide, Ifosfamide,
More informationDefinition of high risk disease for diffuse large B-cell lymphoma is score 4 or 5 based on the following risk factors:
INDICATION High grade lymphoma with high risk of CNS involvement Definition of high risk disease for diffuse large B-cell lymphoma is score 4 or 5 based on the following risk factors: Age > 60 Raised serum
More informationCisplatin and Vinorelbine and radiotherapy (NSCLC)
Cisplatin and Vinorelbine and radiotherapy (NSCLC) Indication First-line chemotherapy for use with concomitant radical radiotherapy for early or locally advanced non-small cell carcinoma (NSCLC) ICD-10
More informationWEIGHT: KG HEIGHT: CM ALLERGY CAUTION sheet reviewed Code Status Full code
(Page 1 of 5) Code Status Full code Status/Admit/Transfer/Discharge Surgical Procedure(s) and date performed: Cardiologist: Cardiac Surgeon: Intensivist: Patient Care CMV status Recipient CMV status Donor
More informationADULT POST NEUROLOGIC INTERVENTION ORDERS 2 of 4
9 Actual 9 Estimated DOWNTIME INTERVENTION 1 of 4 Weight kg 9 Actual 9 Estimated Height cm ALLERGIES: REFER TO ALLERGY PROFILE/ POWERCHART Admit to Dr.: Bed Type: Dx: ( ) Check, circle and/or fill in all
More informationSAALT3W Sarcoma Dr. Meg Knowling. Protocol Code Tumour Group Contact Physician
BCCA Protocol Summary for Etoposide, Ifosfamide-Mesna (SAIME) Alternating with vincristine, DOXOrubicin and Cyclophosphamide (with or without Mesna)(SAVAC or SAVACM) with Filgrastim Support at a THREE
More informationGemcitabine & Cisplatin
Gemcitabine & Cisplatin Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient Indication Advanced
More informationCisplatin / Capecitabine (+ Trastuzumab) in Gastric Cancer
Cisplatin / Capecitabine (+ Trastuzumab) in Gastric Cancer Page 1 of 5 Indication: Confirmed HER2-positive (3+ or FISH+) metastatic adenocarcinoma of the stomach or gastrooesophageal junction. Patient
More informationEC (Epirubicin Cyclophosphamide) Adjuvant/Neo-adjuvant regimen
y Systemic Anti Cancer Treatment Protocol EC (Epirubicin Cyclophosphamide) Adjuvant/Neo-adjuvant regimen PROTOCOL REF: MPHAECANBR (Version No: 1.0) Approved for use in: ER positive, HER2 negative ( Luminal
More informationELIGIBILITY: Newly diagnosed acute promyelocytic leukemia (APL) with low to intermediate risk (WBC less than 10 x 10 9 /L)
BCCA Protocol Summary for First-Line Induction and Consolidation Therapy of Acute Promyelocytic Leukemia Using Arsenic Trioxide and Tretinoin (All-Trans Retinoic Acid) Protocol Code Tumour Group Contact
More information(High dose METHOTREXATE, high dose CYTARABINE, RITUXIMAB and THIOTEPA)
MATRix (High dose METHOTREXATE, high dose CYTARABINE, RITUXIMAB and THIOTEPA) INDICATION CNS Lymphoma. TREATMENT INTENT Curative. PRE-ASSESSMENT 1. Ensure histology is confirmed and documented in the notes.
More informationBevacizumab + Paclitaxel + Cisplatin
Bevacizumab + Paclitaxel + Cisplatin Available for Routine Use in Not routinely commissioned, each case requires prior documented approval before offering & commencing therapy from the Cancer Drugs Fund
More informationALL CONSOLIDATION- Cycle 3 (25-60 years)
ALL CONSOLIDATION- (25-60 years) INDICATION Adult Acute Lymphoblastic Leukaemia (ALL) in remission not eligible for allogeneic transplantation This protocol is suitable for patients aged 25-60 years. It
More informationDONATION AFTER CARDIAC DEATH PLAN
DONATION AFTER CARDIAC DEATH PLAN Diagnosis Weight Allergies Patient Care Core Body Temperature Monitoring Maintain body temp 96-99 degrees Farenheit. Utilize Hyper/Hypothermia blanket prn Insert Gastric
More informationX M/ (R) Dose adjusted (DA)-EPOCH-R
X M/ (R) adjusted (DA)-EPOCH-R Indication High-risk CD20+ diffuse large B cell lymphoma especially C-MYC and BCL-2 activated (i.e. double hit lymphoma) and mediastinal sclerosing (thymic) large B cell
More informationCISPLATIN Chemo-radiation regimen Gynaecological Cancer
Systemic Anti Cancer Treatment Protocol CISPLATIN Chemo-radiation regimen Gynaecological Cancer PROCTOCOL REF: MPHAGYNCIX (Version No: 1.0) Approved for use in: Locally advanced cervical cancer (adjuvant/curative)
More informationBEAM. Lymphoma group OxBMT SCHEDULE SUMMARY. Date:
xbt SCHEDULE SUARY Date: Day DRUG -7-6 -5-4 -3-2 -1 0 +1 Admission Carmustine (BCNU) Etoposide Cytarabine (Ara-C) elphalan Stem cell infusion Pentamidine* To prevent a specific pneumonia called PCP Cyclizine
More informationCisplatin / Paclitaxel Gynaecological Cancer
Systemic Anti Cancer Treatment Protocol Cisplatin / Paclitaxel Gynaecological Cancer PROCTOCOL REF: MPHAGYNCIP (Version No: 1.0) Approved for use in: First line treatment for stage Ib-IV with minimal residual
More informationBurkitt lymphoma, double hit lymphoma or high IPI diffuse large B-cell lymphoma.
INDICATION Burkitt lymphoma, double hit lymphoma or high IPI diffuse large B-cell lymphoma. TREATMENT INTENT Curative. PRE-ASSESSMENT 1. Ensure histology is confirmed prior to administration of chemotherapy
More informationDA-EPOCH-R (Etoposide/Inpatient)
DA- (Etoposide/Inp) INDICATION High grade lymphoma. Omit rituximab if CD20 negative. PRE-ASSESSMENT 1. Ensure histology is confirmed prior to administration of chemotherapy and document in notes. 2. Record
More informationGOOVIPPC. Protocol Code: Gynecology. Tumour Group: Paul Hoskins. Contact Physician: James Conklin. Contact Pharmacist:
BCCA Protocol Summary for Primary Treatment of Stage III less than or equal to 1 cm Visible Residual Invasive Epithelial Ovarian Cancer or Stage I Grade 3 or Stage II Grade 3 Papillary Serous Ovarian Cancer
More informationAdjuvant/Curative/Neo-adjuvant High Grade and Burkitt s Lymphoma Regimens. High Grade Lymphoma
Adjuvant/Curative/Neo-adjuvant High Grade and Burkitt s Lymphoma Regimens The following table lists the evidence-informed regimens (both IV and non-iv) for high grade and Burkitt s lymphoma used in the
More informationThis is a controlled document and therefore must not be changed or photocopied L.80 - R-CHOP-21 / CHOP-21
R- / INDICATION Lymphoma Histiocytosis Omit rituximab if CD20-negative. TREATMENT INTENT Disease modification or curative depending on clinical circumstances PRE-ASSESSMENT 1. Ensure histology is confirmed
More informationCD20-positive high-grade non-hodgkin Lymphoma in patients in which R-CHOP is not indicated
INDICATION CD20-positive high-grade non-hodgkin Lymphoma in patients in which R-CHOP is not indicated TREATMENT INTENT Curative or Disease Modification. PRE-ASSESSMENT 1. Ensure histology is confirmed
More informationFEC-T plus trastuzumab & pertuzumab
Page 1 of 5 Indication Treatment Intent Frequency and number of cycles Monitoring parameters pre-treatment The neoadjuvant treatment of locally advanced, inflammatory or early HER2 positive breast cancer
More informationMATRIX (Methotrexate, Cytarabine, Thiotepa and Rituximab)
MATRIX (Methotrexate, Cytarabine, Thiotepa and Rituximab) Indication First line treatment of primary CNS lymphoma. ICD-10 codes Codes with a prefix C85 Regimen details Day Drug Dose Route 1 and 6 Rituximab
More informationNECN CHEMOTHERAPY HANDBOOK PROTOCOL
DRUG ADMINISTRATION SCHEDULE Day Drug Dose Route Diluent Rate 1* to 5 Prednisolone 40mg/m 2 Oral Once Daily For 5 days 1 Paracetamol 1gram Oral Once Only Chlorphenamine 10mg IV bolus Ondansetron 8mg IV
More informationADMIT DIABETIC KETOACIDOSIS (DKA) PLAN - Phase: Begin Immediately/Emergency Center
- Phase: Begin Immediately/Emergency Center Weight PHYSICIAN S Allergies Admit/Discharge/Transfer Patient Status Requested Location: MICU, Pt Status: Inpatient (LOS > 2 midnights) Requested Location: 5E
More informationTIP: Paclitaxel / Ifosfamide / Cisplatin in Relapsed Germ Cell Tumour
TIP: Paclitaxel / Ifosfamide / Cisplatin in Relapsed Germ Cell Tumour Indication: Second line therapy in Relapsed Germ Cell Tumours Regimen details: Paclitaxel 175mg/m 2 IV Cisplatin 20mg/m 2 IV - D5 Ifosfamide
More information5-FU & Cisplatin + Cetuximab
5-FU & Cisplatin + Cetuximab Available for Routine Use in Not routinely commissioned, each case requires prior documented approval before offering & commencing therapy from either: a) the relevant PCT
More informationNB. This version combines both previous inpatient and ambulatory protocols. See DRUG REGIMEN section for details.
DA- INDICATION High grade lymphoma. Omit rituximab if CD20 negative. NB. This version combines both previous inpatient and ambulatory protocols. See DRUG REGIMEN section for details. TREATMENT INTENT Curative
More informationCarboplatin / Gemcitabine Gynaecological Cancer
Systemic Anti Cancer Treatment Protocol Carboplatin / Gemcitabine Gynaecological Cancer PROCTOCOL REF: MPHAGYNCAG (Version No: 1.0) Approved for use in: Recurrent/metastatic endometrial carcinoma Previously
More informationBCCA Protocol Summary for Treatment of Primary Intracerebral Lymphoma with High Dose Methotrexate and rituximab
BCCA Protocol Summary for Treatment of Primary Intracerebral Lymphoma with High Dose Methotrexate and rituximab Protocol Code Tumour Group Contact Physician LYHDMRP Lymphoma Dr. Diego Villa ELIGIBILITY:
More informationBC Cancer Protocol Summary for Central Nervous System Prophylaxis with High Dose Methotrexate, CHOP and rituximab in Diffuse Large B-cell Lymphoma
BC Cancer Protocol Summary for Central Nervous System Prophylaxis with High Dose Methotrexate, CHOP and rituximab in Diffuse Large B-cell Lymphoma Protocol Code Tumour Group Contact Physician LYCHOPRMTX
More information2.07 Protocol Name: CHOP & Rituximab
2.07 Protocol Name: CHOP & Rituximab Indication Intermediate and high grade, B-cell non-hodgkins lymphoma expressing CD20. Second or third line therapy for low grade, B cell non- Hodgkins lymphoma expressing
More informationBCCA Protocol Summary for Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck Cancer Using Fluorouracil and Platinum
BCCA Protocol Summary for Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck Cancer Using Fluorouracil and Platinum Protocol Code: Tumour Group: Contact Physician: HNAVFUP Head and Neck
More informationWeekly Cisplatin + Radiotherapy - Interlace study -
Weekly Cisplatin + Radiotherapy - Interlace study - A phase III multicentre trial of weekly induction chemotherapy followed by standard chemoradiation versus standard chemoradiation alone in patients with
More information(R) CHOEP. May be used for stage IA - IV Diffuse Large B Cell non-hodgkin lymphoma in combination with rituximab.
(R) CHOEP Indication Treatment of stage IA - IV T cell non-hodgkin lymphoma as an alternative to CHOP in younger, fitter patients with normal LDH level. May be used for stage IA - IV Diffuse Large B Cell
More informationZzbeacon,Zayna [MR ]
AALL1131 MAINTENANCE, ARM B, HR-ALL Properties Laboratory and Take-Home Medications 9/26/2012, Planned Laboratory and Take-Home Medications Planned for 9/26/2012 Release Take-Home Medications prednisone
More informationResearch Implementation Office (RIO) Solid Tumor/Heme/Heme Malignancy Protocol Specific Pre printed Order (PPO) Guidelines
Research Implementation Office Solid Tumor/Heme/Heme Malignancy Protocol Specific Pre printed Order (PPO) Guidelines Note: As of February 11, 2015, the only preprinted orders which remain on paper for
More information1. FBE,UEC, LFT 2. USS of eyes confirm intraocular origin, possible calcifications. 3. CT(if available) of eyes and head
Retinoblastoma PNG V2 Treatment Guidelines for PNG Retinoblastoma 01V1 Current aim of treatment is to preserve life, vision preservation is secondary at this time. Retinoblastoma remains intra ocular and
More informationALL MAINTENANCE (25-60 years)
ALL MAINTENANCE (25-60 years) INDICATION Adult Acute Lymphoblastic Leukaemia (ALL) in remission not eligible for allogeneic transplantation This protocol is suitable for patients aged 25-60 years. It may
More informationDRUG EXTRAVASATION. Vesicants. Irritants
DRUG EXTRAVASATION Vesicants Irritants Vesicants Antineoplastic drugs Amsacrine Dactinomycin Daunorubicin Docetaxel (rare) Doxorubicin Epirubicin Idarubicin Mechlorethamine Mitomycin Oxaliplatin (rare)
More informationCisplatin100 plus Radiotherapy for locally Advanced Squamous Cell Carcinoma Head and Neck
Cisplatin100 plus Radiotherapy for locally Advanced Squamous Cell Carcinoma Head and Neck Indication: 1) Concomitant chemo-radiotherapy for locally advanced squamous cell carcinoma head and neck 2) Post-operative
More informationCarboplatin and Gemcitabine
Systemic Anti Cancer Treatment Protocol Carboplatin and Gemcitabine PROTOCOL REF: MPHACAGELU (Version No: 1.0) Approved for use in: Advanced non-small cell lung cancer Performance status: 0 to 2 Re-challenge
More informationNeurosurgery Pre-Op [1710] Patient Name MRN. General. Nursing. Case Request [ ] Case request operating room Scheduling/ADT, Scheduling/ADT [ ] Other
Neurosurgery Pre-Op [1710] Patient Name MRN General Case Request [ ] Case request operating room Scheduling/ADT, Scheduling/ADT Inpatient Only Procedure (Single Response) ( ) Admit to Inpatient Diagnosis:
More informationStandard Regimens for Haematology
Regimens for Haematology ChlVPP Chlorambucil 6mg/m 2 PO D1 to 14 Vinblastine 6mg/m 2 (max 10mg) IV on D1 & 8 Procarbazine 100mg/m 2 PO on D1 to 14 Prednisolone 40mg PO D1 to 14 ABVD Doxorubicin 25mg/m
More informationEXCLUSIONS: 1. Serum Creatinine above 150 micromol/l or estimated creatinine clearance below 60 ml/min
BCCA Protocol Summary for Treatment of Burkitt Lymphoma and Leukemia (ALL-L3) with Cyclophosphamide, vincristine, DOXOrubicin, Methotrexate, Leucovorin (CODOX-M) and rituximab Protocol Code Tumour Group
More informationHerceptin (Trastuzumab) plus Capecitabine & Cisplatin (HCX)
Herceptin (Trastuzumab) plus Capecitabine & Cisplatin (HCX) DRUG ADMINISTRATION SCHEDULE First Cycle Only: Day Drug Daily Dose Route Diluent and Rate 1 to 21 Capecitabine 625mg/m 2 Day 1 TWICE DAILY Oral
More informationPEDIATRIC LIFEGIFT BRAIN DEATH PLAN
PHYSICIAN S Diagnosis Weight Allergies Admit/Discharge/Transfer THIS PLAN IS TO BE ED ONLY ON THE LIFEGIFT ENCOUNTER, WITH DR LIFEGIFT AS THE ATTENDING. Patient Status Pt Status: Inpatient (Inpatient only
More informationCisplatin / 5-Fluorouracil for Vulval Cancer
Cisplatin / 5-Fluorouracil for Vulval Cancer Indication: Palliative therapy in patients with Vulval Cancer Regimen details: Cisplatin 75mg/m 2 (*) IV 5-Fluorouracil (5-FU) 1000mg/m 2 /24 hours IV D4 (*)Consider
More informationOrgan Donor Management Recommended Guidelines ADULT CARDIAC DEATH (DCD)
Date: Time: = Always applicable = Check if applicable ADMISSION INSTRUCTIONS Move to Comfort Care Note in chart. Contact initiated with BC Transplant Consent for Organ Donation obtained Code Status: Full
More informationClinical Policy: Nabilone (Cesamet) Reference Number: ERX.NPA.35 Effective Date:
Clinical Policy: (Cesamet) Reference Number: ERX.NPA.35 Effective Date: 09.01.17 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More information